MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Eli Lilly and Co.

Отворен

СекторЗдравеопазване

866.65 2.07

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

845.8

Максимум

871.37

Ключови измерители

By Trading Economics

Приходи

7.8B

8.8B

Продажби

2.1B

14B

P/E

Средно за сектора

70.036

57.333

EPS

5.32

Дивидентна доходност

0.71

Марж на печалбата

65.172

Служители

47,000

EBITDA

1.2B

6.1B

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+16.73% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

0.71%

2.63%

Следващи печалби

1.05.2025 г.

Следваща дата на екс-дивидент

14.05.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-50B

735B

Предишно отваряне

864.58

Предишно затваряне

866.65

Техническа оценка

By Trading Central

Увереност

Very Strong Bullish Evidence

Eli Lilly and Co. Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

22.04.2025 г., 09:26 ч. UTC

Значими двигатели на пазара

Novo Nordisk Shares Fall After Data From New Eli Lilly Pill

18.04.2025 г., 15:57 ч. UTC

Значими двигатели на пазара

Eli Lilly CEO Ricks Warns Against Unintentionally Raising Prices as Weight-Loss Pill Nears Market Launch

17.04.2025 г., 11:52 ч. UTC

Значими двигатели на пазара

Eli Lilly Shares Jump Premarket After First Pill for Diabetes, Weight Loss Shows Positive Study Results

9.04.2025 г., 18:18 ч. UTC

Значими двигатели на пазара

Pharma Shares Reverse Losses After Tariff Pause

9.04.2025 г., 09:39 ч. UTC

Значими двигатели на пазара

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

4.04.2025 г., 22:38 ч. UTC

Горещи акции

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

1.04.2025 г., 23:15 ч. UTC

Значими двигатели на пазара

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

22.04.2025 г., 09:31 ч. UTC

Горещи акции

Stocks to Watch Tuesday: Tesla, Novo Nordisk, Hertz -- WSJ

17.04.2025 г., 18:27 ч. UTC

Топ новини

Lilly's First Pill for Diabetes, Weight Loss Shows Positive Study Results -- Update

17.04.2025 г., 10:45 ч. UTC

Топ новини

Lilly's First Pill for Diabetes, Weight Loss Shows Positive Study Results -- WSJ

11.04.2025 г., 16:23 ч. UTC

Придобивния, сливания и поглъщания

Novo Remade Denmark. Then Came the Stock Selloff. -2-

11.04.2025 г., 16:23 ч. UTC

Придобивния, сливания и поглъщания

Novo Remade Denmark. Then Came the Stock Selloff. -- Barrons.com

11.04.2025 г., 09:30 ч. UTC

Топ новини

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

11.04.2025 г., 05:00 ч. UTC

Топ новини

Wall Street Pulls Back on the Weight-Loss Drug Hype -- Barrons.com

10.04.2025 г., 05:00 ч. UTC

Печалби

Amgen Is Getting Into the Obesity Drug Business. Buy the Stock Before It Becomes the Next Winner. -- Barrons.com

8.04.2025 г., 21:26 ч. UTC

Печалби

Pfizer Stock's Fall to '97 Level Lifts Yield Near 8%. Dividend Looks Safe. -- Barrons.com

2.04.2025 г., 16:53 ч. UTC

Топ новини

Hims & Hers Zepbound Offering Won't Bring Needed Sales Boom -- Analysis

1.04.2025 г., 22:31 ч. UTC

Топ новини

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

1.04.2025 г., 21:47 ч. UTC

Топ новини

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

19.03.2025 г., 15:54 ч. UTC

Топ новини

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

14.03.2025 г., 09:30 ч. UTC

Топ новини

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

28.02.2025 г., 12:00 ч. UTC

Топ новини

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

26.02.2025 г., 15:14 ч. UTC

Топ новини

Eli Lilly Plans to Spend $27 Billion on New U.S. Plants -- Update

26.02.2025 г., 14:30 ч. UTC

Топ новини

Eli Lilly Plans to Spend $27 Billion on New U.S. Plants -- WSJ

10.02.2025 г., 12:00 ч. UTC

Топ новини

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

7.02.2025 г., 10:30 ч. UTC

Топ новини

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

6.02.2025 г., 16:16 ч. UTC

Топ новини
Печалби

The Obesity Market Is Growing Just Fine. But Investors Want to Know What's Next -- Heard on the Street -- WSJ

6.02.2025 г., 14:56 ч. UTC

Печалби

Eli Lilly's Disappointing Quarter Was Already Baked In -- Barrons.com

6.02.2025 г., 14:32 ч. UTC

Пазарно говорене
Печалби

Lilly's Weight-Loss Drug Bonanza Continues -- Market Talk

6.02.2025 г., 13:18 ч. UTC

Топ новини
Печалби

Eli Lilly Stock Rises After Earnings Beat Forecasts -- WSJ

Сравнение с други в отрасъла

Ценова промяна

Eli Lilly and Co. Прогноза

Ценова цел

By TipRanks

16.73% нагоре

12-месечна прогноза

Среден 1,003.6 USD  16.73%

Висок 1,124 USD

Нисък 888 USD

Според 19 анализатори от Wall Street, предложили 12-месечна ценова цел за Eli Lilly and Co. през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

19 ratings

19

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

732.41 / N/AПодкрепа & съпротива

Краткосрочен план

Very Strong Bullish Evidence

Средносрочен план

Bullish Evidence

Дългосрочен план

Bearish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.